| |
| Tumor Necrosis Factor alpha (TNF)-α (mutant), human |
|
|
| Catalog No. |
Size |
Price |
Figures |
|---|
Z00404-10 ug
| 10 ug | $ 91.00 | |
|---|
Z00404-50 ug
| 50 ug | $ 260.00 |
|---|
Z00404-1 mg
| 1 mg | $ 1560.00 |
|---|
| Full Name | | Tumor Necrosis Factor alpha (TNF)-α (mutant), human |
| | Abbreviated Name-1 | Tumor Necrosis Factor alpha (TNF)-α (mutant), human |
|---|
| Abbreviated Name-2 | TNF-alpha mutant, human |
|---|
| Description | TNF is secreted by macrophages, monocytes, neutrophils, T-cells, NK-cells following their stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-alpha while CD8 cells secrete little or no TNF-alpha. The synthesis of TNF-alpha is induced by many different stimuli including interferons, IL2, GM-CSF.
The clinical use of the potent anti-tumor activity of TNF-alpha has been limited by the proinflammatory side effects including fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-a mutants with low systemic toxicity has been an intense pharmacological interest. Human TNF-a, which binds to the murine TNF-R55 but not to the mouse TNF-R75, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-a, which binds to both murine TNF receptors. Based on these results, many TNF-a mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro, and exhibited lower systemic toxicity in vivo. Recombinant Human TNF-alpha Variant/Mutant compared with the wild-type, has an amino acid sequence deletion from a.a. 1-7, and the following a.a. substitutes Arg8, Lys9, Arg10 and Phe157 which is proven to have more activity and with less inflammatory side effect in vivo. Recombinant Human TNF-alpha Mutant produced in E. coli is a single, non-glycosylated, polypeptide chain containing 151 amino acids and having a molecular mass of 16,886 Da. |
|---|
| Source | E. coli |
|---|
| M.W. | 16,886 Da |
|---|
| Purity | Greater than 95.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.
|
|---|
| Endotoxin Level | Less than 0.01 ng/µg (0.01 IEU/µg) determined by LAL test |
|---|
| Specific Activity | The ED50 as determined by the cytolysis of murine L929 cells in the presence of Actinomycin D is less than 0.01 ng/ml, corresponding to a Specific Activity of 1.0×108 IU/mg. |
|---|
| Storage | Lyophilized samples are stable for up to twelve months from date of receipt at -20oC to -70°C. Please avoid repeated freeze-thaw cycles. |
|---|
| Formulation | Lyophilized from a 0.2 µm filtered solution in PBS |
|---|
| Reconstitution | It is recommended to reconstitute the lyophilized rHuTNF-alpha mutant in sterile 18 MΩ-cm H2O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions. |
|---|
| Quantitation | |
|---|
| Sequence analysis | The sequence of the first five N-terminal amino acids was determined and was found to be Met-Arg-Lys-Arg-Lys.
|
|---|
|
